{
  "study_id": "10.1200/JCO.2013.54.5392",
  "study_title": "Randomized Phase III Trial of Amrubicin Versus Topotecan As Second-Line Treatment for Patients With Small-Cell Lung Cancer",
  "table_name": "Table 1",
  "table_title": "Patient Demographic and Clinical Characteristics at Baseline (ITT population)",
  "description": "Patient demographic and clinical characteristics for the Intent-to-Treat (ITT) population at baseline.",
  "footnotes": [
    "Abbreviations: CR, complete response; ECOG PS, Eastern Cooperative Oncology Group performance status; ITT, intent to treat; PD, progressive disease; PR, partial response; SCLC, small-cell lung cancer; SD, stable disease."
  ],
  "groups": [
    {
      "name": "Amrubicin",
      "n": 424,
      "type": "intervention"
    },
    {
      "name": "Topotecan",
      "n": 213,
      "type": "intervention"
    }
  ],
  "characteristics": [
    {
      "original_label": "Age, years",
      "standardized_name": "Age",
      "unit": "years",
      "category": "Demographics",
      "group_data": [
        {
          "group_name": "Amrubicin",
          "data_type": "header",
          "raw_string": "Age, years"
        },
        {
          "group_name": "Topotecan",
          "data_type": "header",
          "raw_string": "Age, years"
        }
      ]
    },
    {
      "original_label": "Median",
      "standardized_name": "Age",
      "unit": "years",
      "category": "Demographics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Age, years",
      "group_data": [
        {
          "group_name": "Amrubicin",
          "data_type": "numeric_single",
          "value": 62.0,
          "raw_string": "62"
        },
        {
          "group_name": "Topotecan",
          "data_type": "numeric_single",
          "value": 61.0,
          "raw_string": "61"
        }
      ]
    },
    {
      "original_label": "Range",
      "standardized_name": "Age Range",
      "unit": "years",
      "category": "Demographics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Age, years",
      "group_data": [
        {
          "group_name": "Amrubicin",
          "data_type": "numeric_mean_range",
          "range_min": 22.0,
          "range_max": 81.0,
          "raw_string": "22-81"
        },
        {
          "group_name": "Topotecan",
          "data_type": "numeric_mean_range",
          "range_min": 30.0,
          "range_max": 81.0,
          "raw_string": "30-81"
        }
      ]
    },
    {
      "original_label": "≥ 65",
      "standardized_name": "Age >= 65 years",
      "category": "Demographics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Age, years",
      "group_data": [
        {
          "group_name": "Amrubicin",
          "data_type": "categorical_count_percentage",
          "count": 169.0,
          "percentage": 39.9,
          "raw_string": "169"
        },
        {
          "group_name": "Topotecan",
          "data_type": "categorical_count_percentage",
          "count": 74.0,
          "percentage": 34.7,
          "raw_string": "74"
        }
      ]
    },
    {
      "original_label": "≥ 75",
      "standardized_name": "Age >= 75 years",
      "category": "Demographics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Age, years",
      "group_data": [
        {
          "group_name": "Amrubicin",
          "data_type": "categorical_count_percentage",
          "count": 32.0,
          "percentage": 7.5,
          "raw_string": "32"
        },
        {
          "group_name": "Topotecan",
          "data_type": "categorical_count_percentage",
          "count": 12.0,
          "percentage": 5.6,
          "raw_string": "12"
        }
      ]
    },
    {
      "original_label": "Male sex",
      "standardized_name": "Sex",
      "category": "Demographics",
      "group_data": [
        {
          "group_name": "Amrubicin",
          "data_type": "categorical_count_percentage",
          "male_count": 244.0,
          "text_value": "Male",
          "raw_string": "244",
          "notes": "The table specifies counts for 'Male sex'",
          "n_for_value": 424
        },
        {
          "group_name": "Topotecan",
          "data_type": "categorical_count_percentage",
          "male_count": 127.0,
          "text_value": "Male",
          "raw_string": "127",
          "notes": "The table specifies counts for 'Male sex'",
          "n_for_value": 213
        }
      ]
    },
    {
      "original_label": "ECOG PS",
      "standardized_name": "ECOG Performance Status",
      "category": "Baseline Characteristics",
      "group_data": [
        {
          "group_name": "Amrubicin",
          "data_type": "header",
          "raw_string": "ECOG PS"
        },
        {
          "group_name": "Topotecan",
          "data_type": "header",
          "raw_string": "ECOG PS"
        }
      ]
    },
    {
      "original_label": "0",
      "standardized_name": "ECOG Performance Status 0",
      "category": "Baseline Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "ECOG PS",
      "group_data": [
        {
          "group_name": "Amrubicin",
          "data_type": "categorical_count_percentage",
          "count": 126.0,
          "percentage": 29.7,
          "raw_string": "126"
        },
        {
          "group_name": "Topotecan",
          "data_type": "categorical_count_percentage",
          "count": 72.0,
          "percentage": 33.8,
          "raw_string": "72"
        }
      ]
    },
    {
      "original_label": "1",
      "standardized_name": "ECOG Performance Status 1",
      "category": "Baseline Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "ECOG PS",
      "group_data": [
        {
          "group_name": "Amrubicin",
          "data_type": "categorical_count_percentage",
          "count": 289.0,
          "percentage": 68.2,
          "raw_string": "289"
        },
        {
          "group_name": "Topotecan",
          "data_type": "categorical_count_percentage",
          "count": 137.0,
          "percentage": 64.3,
          "raw_string": "137"
        }
      ]
    },
    {
      "original_label": "2",
      "standardized_name": "ECOG Performance Status 2",
      "category": "Baseline Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "ECOG PS",
      "group_data": [
        {
          "group_name": "Amrubicin",
          "data_type": "categorical_count_percentage",
          "count": 9.0,
          "percentage": 2.1,
          "raw_string": "9"
        },
        {
          "group_name": "Topotecan",
          "data_type": "categorical_count_percentage",
          "count": 4.0,
          "percentage": 1.9,
          "raw_string": "4"
        }
      ]
    },
    {
      "original_label": "Actual disease stage",
      "standardized_name": "Disease Stage",
      "category": "Baseline Characteristics",
      "group_data": [
        {
          "group_name": "Amrubicin",
          "data_type": "header",
          "raw_string": "Actual disease stage"
        },
        {
          "group_name": "Topotecan",
          "data_type": "header",
          "raw_string": "Actual disease stage"
        }
      ]
    },
    {
      "original_label": "Limited",
      "standardized_name": "Limited Disease Stage",
      "category": "Baseline Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Actual disease stage",
      "group_data": [
        {
          "group_name": "Amrubicin",
          "data_type": "categorical_count_percentage",
          "count": 53.0,
          "percentage": 12.5,
          "raw_string": "53"
        },
        {
          "group_name": "Topotecan",
          "data_type": "categorical_count_percentage",
          "count": 26.0,
          "percentage": 12.2,
          "raw_string": "26"
        }
      ]
    },
    {
      "original_label": "Extensive",
      "standardized_name": "Extensive Disease Stage",
      "category": "Baseline Characteristics",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Actual disease stage",
      "group_data": [
        {
          "group_name": "Amrubicin",
          "data_type": "categorical_count_percentage",
          "count": 371.0,
          "percentage": 87.5,
          "raw_string": "371"
        },
        {
          "group_name": "Topotecan",
          "data_type": "categorical_count_percentage",
          "count": 187.0,
          "percentage": 87.8,
          "raw_string": "187"
        }
      ]
    },
    {
      "original_label": "Time from SCLC diagnosis, months",
      "standardized_name": "Time from SCLC diagnosis",
      "unit": "months",
      "category": "Disease History",
      "group_data": [
        {
          "group_name": "Amrubicin",
          "data_type": "header",
          "raw_string": "Time from SCLC diagnosis, months"
        },
        {
          "group_name": "Topotecan",
          "data_type": "header",
          "raw_string": "Time from SCLC diagnosis, months"
        }
      ]
    },
    {
      "original_label": "Median",
      "standardized_name": "Time from SCLC diagnosis",
      "unit": "months",
      "category": "Disease History",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Time from SCLC diagnosis, months",
      "group_data": [
        {
          "group_name": "Amrubicin",
          "data_type": "numeric_single",
          "value": 8.4,
          "raw_string": "8.4"
        },
        {
          "group_name": "Topotecan",
          "data_type": "numeric_single",
          "value": 8.4,
          "raw_string": "8.4"
        }
      ]
    },
    {
      "original_label": "Range",
      "standardized_name": "Time from SCLC diagnosis Range",
      "unit": "months",
      "category": "Disease History",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Time from SCLC diagnosis, months",
      "group_data": [
        {
          "group_name": "Amrubicin",
          "data_type": "numeric_mean_range",
          "range_min": 1.2,
          "range_max": 108.0,
          "raw_string": "1.2-108"
        },
        {
          "group_name": "Topotecan",
          "data_type": "numeric_mean_range",
          "range_min": 1.6,
          "range_max": 49.6,
          "raw_string": "1.6-49.6"
        }
      ]
    },
    {
      "original_label": "Smoking status",
      "standardized_name": "Smoking Status",
      "category": "Lifestyle Factors",
      "group_data": [
        {
          "group_name": "Amrubicin",
          "data_type": "header",
          "raw_string": "Smoking status"
        },
        {
          "group_name": "Topotecan",
          "data_type": "header",
          "raw_string": "Smoking status"
        }
      ]
    },
    {
      "original_label": "Current",
      "standardized_name": "Current Smoker",
      "category": "Lifestyle Factors",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Smoking status",
      "group_data": [
        {
          "group_name": "Amrubicin",
          "data_type": "categorical_count_percentage",
          "count": 126.0,
          "percentage": 29.7,
          "raw_string": "126"
        },
        {
          "group_name": "Topotecan",
          "data_type": "categorical_count_percentage",
          "count": 49.0,
          "percentage": 23.0,
          "raw_string": "49"
        }
      ]
    },
    {
      "original_label": "Former",
      "standardized_name": "Former Smoker",
      "category": "Lifestyle Factors",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Smoking status",
      "group_data": [
        {
          "group_name": "Amrubicin",
          "data_type": "categorical_count_percentage",
          "count": 253.0,
          "percentage": 59.7,
          "raw_string": "253"
        },
        {
          "group_name": "Topotecan",
          "data_type": "categorical_count_percentage",
          "count": 140.0,
          "percentage": 65.7,
          "raw_string": "140"
        }
      ]
    },
    {
      "original_label": "Never",
      "standardized_name": "Never Smoker",
      "category": "Lifestyle Factors",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Smoking status",
      "group_data": [
        {
          "group_name": "Amrubicin",
          "data_type": "categorical_count_percentage",
          "count": 45.0,
          "percentage": 10.6,
          "raw_string": "45"
        },
        {
          "group_name": "Topotecan",
          "data_type": "categorical_count_percentage",
          "count": 24.0,
          "percentage": 11.3,
          "raw_string": "24"
        }
      ]
    },
    {
      "original_label": "First-line chemotherapy",
      "standardized_name": "First-line chemotherapy",
      "category": "Prior Treatment",
      "group_data": [
        {
          "group_name": "Amrubicin",
          "data_type": "header",
          "raw_string": "First-line chemotherapy"
        },
        {
          "group_name": "Topotecan",
          "data_type": "header",
          "raw_string": "First-line chemotherapy"
        }
      ]
    },
    {
      "original_label": "Median No. of cycles",
      "standardized_name": "Median Number of First-line Chemotherapy Cycles",
      "category": "Prior Treatment",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "First-line chemotherapy",
      "group_data": [
        {
          "group_name": "Amrubicin",
          "data_type": "numeric_single",
          "value": 6.0,
          "raw_string": "6"
        },
        {
          "group_name": "Topotecan",
          "data_type": "numeric_single",
          "value": 5.0,
          "raw_string": "5"
        }
      ]
    },
    {
      "original_label": "Response",
      "standardized_name": "Response to First-line chemotherapy",
      "category": "Prior Treatment",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "First-line chemotherapy",
      "group_data": [
        {
          "group_name": "Amrubicin",
          "data_type": "header",
          "raw_string": "Response"
        },
        {
          "group_name": "Topotecan",
          "data_type": "header",
          "raw_string": "Response"
        }
      ]
    },
    {
      "original_label": "CR",
      "standardized_name": "Complete Response to First-line Chemotherapy",
      "category": "Prior Treatment",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Response",
      "group_data": [
        {
          "group_name": "Amrubicin",
          "data_type": "categorical_count_percentage",
          "count": 54.0,
          "percentage": 12.7,
          "raw_string": "54"
        },
        {
          "group_name": "Topotecan",
          "data_type": "categorical_count_percentage",
          "count": 33.0,
          "percentage": 15.5,
          "raw_string": "33"
        }
      ]
    },
    {
      "original_label": "PR",
      "standardized_name": "Partial Response to First-line Chemotherapy",
      "category": "Prior Treatment",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Response",
      "group_data": [
        {
          "group_name": "Amrubicin",
          "data_type": "categorical_count_percentage",
          "count": 239.0,
          "percentage": 56.4,
          "raw_string": "239"
        },
        {
          "group_name": "Topotecan",
          "data_type": "categorical_count_percentage",
          "count": 105.0,
          "percentage": 49.3,
          "raw_string": "105"
        }
      ]
    },
    {
      "original_label": "SD",
      "standardized_name": "Stable Disease to First-line Chemotherapy",
      "category": "Prior Treatment",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Response",
      "group_data": [
        {
          "group_name": "Amrubicin",
          "data_type": "categorical_count_percentage",
          "count": 84.0,
          "percentage": 19.8,
          "raw_string": "84"
        },
        {
          "group_name": "Topotecan",
          "data_type": "categorical_count_percentage",
          "count": 49.0,
          "percentage": 23.0,
          "raw_string": "49"
        }
      ]
    },
    {
      "original_label": "PD",
      "standardized_name": "Progressive Disease to First-line Chemotherapy",
      "category": "Prior Treatment",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Response",
      "group_data": [
        {
          "group_name": "Amrubicin",
          "data_type": "categorical_count_percentage",
          "count": 47.0,
          "percentage": 11.1,
          "raw_string": "47"
        },
        {
          "group_name": "Topotecan",
          "data_type": "categorical_count_percentage",
          "count": 25.0,
          "percentage": 11.7,
          "raw_string": "25"
        }
      ]
    },
    {
      "original_label": "Missing",
      "standardized_name": "Missing Response to First-line Chemotherapy",
      "category": "Prior Treatment",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Response",
      "group_data": [
        {
          "group_name": "Amrubicin",
          "data_type": "categorical_count_percentage",
          "count": 0.0,
          "percentage": 0.0,
          "raw_string": "0"
        },
        {
          "group_name": "Topotecan",
          "data_type": "categorical_count_percentage",
          "count": 1.0,
          "percentage": 0.5,
          "raw_string": "1"
        }
      ]
    },
    {
      "original_label": "Prior radiotherapy",
      "standardized_name": "Prior radiotherapy",
      "category": "Prior Treatment",
      "group_data": [
        {
          "group_name": "Amrubicin",
          "data_type": "categorical_count_percentage",
          "count": 200.0,
          "percentage": 47.2,
          "raw_string": "200"
        },
        {
          "group_name": "Topotecan",
          "data_type": "categorical_count_percentage",
          "count": 106.0,
          "percentage": 49.8,
          "raw_string": "106"
        }
      ]
    },
    {
      "original_label": "Response to prior first-line therapy",
      "standardized_name": "Response to prior first-line therapy",
      "category": "Prior Treatment",
      "group_data": [
        {
          "group_name": "Amrubicin",
          "data_type": "header",
          "raw_string": "Response to prior first-line therapy"
        },
        {
          "group_name": "Topotecan",
          "data_type": "header",
          "raw_string": "Response to prior first-line therapy"
        }
      ]
    },
    {
      "original_label": "Sensitive",
      "standardized_name": "Sensitive Response to prior first-line therapy",
      "category": "Prior Treatment",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Response to prior first-line therapy",
      "group_data": [
        {
          "group_name": "Amrubicin",
          "data_type": "categorical_count_percentage",
          "count": 225.0,
          "percentage": 53.1,
          "raw_string": "225"
        },
        {
          "group_name": "Topotecan",
          "data_type": "categorical_count_percentage",
          "count": 117.0,
          "percentage": 54.9,
          "raw_string": "117"
        }
      ]
    },
    {
      "original_label": "Refractory",
      "standardized_name": "Refractory Response to prior first-line therapy",
      "category": "Prior Treatment",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Response to prior first-line therapy",
      "group_data": [
        {
          "group_name": "Amrubicin",
          "data_type": "categorical_count_percentage",
          "count": 199.0,
          "percentage": 46.9,
          "raw_string": "199"
        },
        {
          "group_name": "Topotecan",
          "data_type": "categorical_count_percentage",
          "count": 96.0,
          "percentage": 45.1,
          "raw_string": "96"
        }
      ]
    },
    {
      "original_label": "Time from end of first-line treatment to PD, days",
      "standardized_name": "Time from end of first-line treatment to Progressive Disease",
      "unit": "days",
      "category": "Disease History",
      "group_data": [
        {
          "group_name": "Amrubicin",
          "data_type": "header",
          "raw_string": "Time from end of first-line treatment to PD, days"
        },
        {
          "group_name": "Topotecan",
          "data_type": "header",
          "raw_string": "Time from end of first-line treatment to PD, days"
        }
      ]
    },
    {
      "original_label": "Median",
      "standardized_name": "Time from end of first-line treatment to Progressive Disease",
      "unit": "days",
      "category": "Disease History",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Time from end of first-line treatment to PD, days",
      "group_data": [
        {
          "group_name": "Amrubicin",
          "data_type": "numeric_single",
          "value": 96.0,
          "raw_string": "96.0"
        },
        {
          "group_name": "Topotecan",
          "data_type": "numeric_single",
          "value": 107.0,
          "raw_string": "107.0"
        }
      ]
    },
    {
      "original_label": "< 90",
      "standardized_name": "Time from end of first-line treatment to PD < 90 days",
      "category": "Disease History",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Time from end of first-line treatment to PD, days",
      "group_data": [
        {
          "group_name": "Amrubicin",
          "data_type": "categorical_count_percentage",
          "count": 197.0,
          "percentage": 46.5,
          "raw_string": "197"
        },
        {
          "group_name": "Topotecan",
          "data_type": "categorical_count_percentage",
          "count": 93.0,
          "percentage": 43.7,
          "raw_string": "93"
        }
      ]
    },
    {
      "original_label": "≥ 90",
      "standardized_name": "Time from end of first-line treatment to PD >= 90 days",
      "category": "Disease History",
      "is_sub_characteristic": true,
      "sub_characteristic_of": "Time from end of first-line treatment to PD, days",
      "group_data": [
        {
          "group_name": "Amrubicin",
          "data_type": "categorical_count_percentage",
          "count": 227.0,
          "percentage": 53.5,
          "raw_string": "227"
        },
        {
          "group_name": "Topotecan",
          "data_type": "categorical_count_percentage",
          "count": 120.0,
          "percentage": 56.3,
          "raw_string": "120"
        }
      ]
    }
  ]
}